Creating Research and Development and Cross-Business Synergies Through Capital and Business Alliances
First written in FY2016. 5 of 9 entries say "Advanced", first in FY2019. Latest entry: FY2026.
24 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「In July 2025, we entered into a business alliance with 株式会社エーセル to build an integrated safety and efficacy evaluation service combining animal and cell testing data and establish a system capable of providing evidence directly linked to clinical trial planning from the early stages of development.」
We have reaffirmed the business alliance with エーセル to build an integrated evaluation service combining animal and cell testing. - 2026-05-13AdvancedEarnings
「In July 2025, we entered into a business partnership with エーセル to establish a framework capable of providing evidence directly linked to the planning of clinical trials from the early stages of development, by building an integrated safety and efficacy evaluation service combining data from animal and cell-based studies.」
The company reconfirmed the purpose and timing of its business partnership with エーセル to build an integrated evaluation service. - FY2026-H1AdvancedAnnual report
「In July 2025, we entered into a business alliance with 株式会社エーセル to build an integrated safety and efficacy evaluation service combining animal and cell testing data and establish a system capable of providing evidence directly linked to clinical trial planning from the early stages of development.」
As part of our efforts to create research and development and business synergies, we entered into a business alliance with 株式会社エーセル to build an integrated safety and efficacy evaluation service combining animal and cell testing. - FY2021RestatedAnnual report
「At 医化学創薬株式会社, we had been working on a project to develop antibodies against the novel coronavirus. Using a glycopeptide antigen as the immunogen, we successfully obtained antibodies targeting glycosylation sites less prone to mutation in the SARS-CoV-2 spike protein, and began selling the antibodies in January 2021 to domestic and overseas diagnostic reagent manufacturers and pharmaceutical companies.」
We have reaffirmed the successful antibody discovery and the launch of sales to domestic and overseas companies in January 2021 in connection with research and development and business collaboration with 医化学創薬. - FY2021-Q3AdvancedAnnual report
「At 医化学創薬株式会社, we had been working on a project to develop antibodies against the novel coronavirus. Using a glycopeptide antigen as the immunogen, we successfully obtained antibodies targeting glycosylation sites less prone to mutation in the SARS-CoV-2 spike protein, and began selling the antibodies in January 2021 to domestic and overseas diagnostic reagent manufacturers and pharmaceutical companies.」
In our initiative with 医化学創薬, previously our capital and business alliance partner, we successfully obtained antibodies against the novel coronavirus and progressed to the launch of sales to domestic and overseas companies in January 2021. - FY2021-Q1AdvancedAnnual report
「During the current first quarter, 医化学創薬株式会社, formerly an equity-method affiliate, became a subsidiary under the substantive control criterion and has therefore been included in the scope of consolidation.」
医化学創薬株式会社, previously our capital and business alliance partner, became a subsidiary, changing its position within the group in terms of research and development and business collaboration. - FY2019AdvancedAnnual report
「Subscription to capital increase (Note)」
We subscribed to 2,000 shares issued in 医化学創薬’s third-party allotment and made an additional investment of ¥80 million. We are expanding the foundation for research and development and business synergies through the capital and business alliance. - FY2017RestatedAnnual report
「We will strengthen collaboration with 医化学創薬㈱, our equity-method affiliate, and focus on creating synergies among the group’s businesses.」
We have reaffirmed our policy of creating synergies between the research and development and contract businesses based on the capital and business alliance with 医化学創薬. - FY2016First statedAnnual report
「As an initiative in a new business, on 30 June of the previous year we entered into a capital and business alliance agreement with 医化学創薬㈱, which has glycopeptide synthesis technology and is headquartered in Sapporo, Hokkaido. On 1 July of the same year, we acquired shares through a third-party allotment and made the company an equity-method affiliate.」
Through our investment in 医化学創薬, which has glycopeptide synthesis technology, we are building a foundation for collaboration with our research and development and contract businesses.